Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
QDX Technologies has developed Rush, an exascale-ready cloud-native computational drug discovery platform that integrates quantum chemistry simulations and AI-driven analytics. It enables rapid molecular modeling, virtual screening, lead optimization, and binding affinity prediction for pharmaceutical R&D teams. The technology has been validated through commercial deals with pharma companies in Australia, Singapore, and the US within its first year of operation[1][2][3][5][8]. No clinical results as it is not a therapeutic developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on QDX Technologies.